Targeting Pathogenic TAR DNA-binding Protein 43 To Treat Frontotemporal Dementia And Motor Neuron Disease
Funder
National Health and Medical Research Council
Funding Amount
$687,444.00
Summary
Frontotemporal dementia and motor neuron Disease are rapidly progressive and fatal neurodegenerative diseases that affect people in their prime. Poor understanding of the processes that lead to these diseases have slowed drug development. Through innovative experimental design, we aim to decipher a novel disease mechanism that involves specific molecular interactions and translate these findings into new therapies for the diseases.
Gamma Delta T Cells: The Fourth Player In CD8 T Cell Immunity
Funder
National Health and Medical Research Council
Funding Amount
$1,020,777.00
Summary
The immune systems of animals have evolved complex but effective mechanisms to protect against infection with intracellular pathogens. This requires that T cells can distinguish uninfected cells from those harbouring pathogens. This is achieved via recognition of pathogen-derived molecules, which activate the immune system to recognise and fight the pathogen. We have identified a crucial role for a gamma delta T cells in this process, making them essential sentinels of intracellular infection.
Nanoengineered Bioelectronic Systems For All-Optical Control Of Neuron Growth And Stimulation
Funder
National Health and Medical Research Council
Funding Amount
$757,452.00
Summary
Nerve cells are the primary signal carriers of the human body. When they cease to function normally, our bodies ability to function and sense the physical world is influenced catastrophically. We will develop a new bioelectronic system made by printing clever inks that can artificially stimulate nerve cells without the typical requirements for invasive metal electrodes or external power. These new scientific advances will revolutionize nerve cell repair and treatment of neurological disorders.
Characterising The Function Of Niche-derived Neuregulin 1 In Colorectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$994,246.00
Summary
Colorectal cancer affects thousands of Australians each year. A specialised cell population, named cancer stem cells, continuously produces new tumour cells. Defining mechanisms controlling the behaviour of these unique cells is critical to develop new drugs. We have identified that Neuregulin-1 is a key factor that enhances the action of cancer stem cells. We aim to study how colorectal cancer is mediated and whether targeting Neuregulin-1 is a promising therapeutic option.
Characterisation And Targeting T Cellular Metabolism To Improve Control Of Chronic Viral Infections
Funder
National Health and Medical Research Council
Funding Amount
$791,427.00
Summary
CD8+ T cells are the frontline warriors of our immune system that can eliminate infected or cancerous cells. However, diseases caused by overwhelming viral infections are associated with widespread impairments in immunity and cellular metabolism. Here, we propose to examine molecular pathways involved in cellular metabolism that could be utilized to improve therapies against viral infection and cancer.
Developing An In Vitro Model Of A Human Blastocyst
Funder
National Health and Medical Research Council
Funding Amount
$890,062.00
Summary
Using novel cellular and molecular technologies we propose to develop an artificial model of an early human blastocyst. This will allow us to study the first initial steps in human development without the use of real embryos. Such a model will not only help us decipher the first steps in human development, but we anticipate it will be essential to study how gene mutations and the environment affect this initial step in human development.
Vaccine To Prevent Influenza Virus And Bacterial Super-infection.
Funder
National Health and Medical Research Council
Funding Amount
$707,717.00
Summary
Influenza viruses have the ability to pre-dispose infected hosts toward secondary bacterial complications. The mortality of viral infections that are complicated by a concurrent, or subsequent, bacterial infection (known as a super-infection), is often greater than that of either the virus or the bacteria alone. We will develop a novel multi-pathogen vaccine candidate against the major upper respiratory tract pathogens - Influenza A and Streptococcus pyogenes to prevent super-infections.
Growth Factor Directed Developmental And Pathological Lymphangiogenesis
Funder
National Health and Medical Research Council
Funding Amount
$1,048,507.00
Summary
The formation of new lymphatic vessels occurs in normal development and in diseased tissues in cancer and cardiovascular disease. We have developed an understanding of how lymphatics form in development but we understand far less about how they form in disease. This project will apply multidisciplinary approaches, including genetics and computational biology, to compare how lymphatics form in development and disease. We hope to uncover new ways to manipulate this process for therapeutic gain.
Relaxin Receptor Structural Determination To Aid Therapeutic Development
Funder
National Health and Medical Research Council
Funding Amount
$1,249,114.00
Summary
The receptor for the peptide hormone relaxin, RXFP1, is being targeted by numerous drug companies for the treatment of cardiovascular disease. However, the lack of molecular detail of how relaxin binds and activates RXFP1 is hindering new drug development. We will determine the structure of the complex of relaxin bound to RXFP1 and the mechanism by which this activates cells. The knowledge gained will aid in the design of new drugs targeting RXFP1 for the treatment of cardiovascular disease.
Harnessing The Benefits Of Autonomous Vehicles For Health
Funder
National Health and Medical Research Council
Funding Amount
$738,596.00
Summary
The arrival of autonomous vehicles (AVs) will have huge implications for health behaviours, including physical activity and diet. It is critical that appropriate planning processes are undertaken as early as possible to prevent cities of the future being designed around AVs rather than people, thereby losing the potential for this new technology to be harnessed as a means of enhancing health. This project will facilitate the inclusion of health considerations in AV implementation processes.